Ultragenyx Pharmaceutical Inc. (RARE) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 10.66
30Y Low3.6·High14.5
ROE
↓
-607.5%
↑-160% vs avg
5yr avg: -233.4%
30Y Low-212%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RARE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ultragenyx Pharmaceutical Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.6B | $2.3B | $3.8B | $3.5B | $3.2B | $5.7B | $8.4B | $2.4B | $2.2B | $2.0B | $2.8B |
| Enterprise Value | $3.4B | $3.1B | $3.7B | $3.3B | $3.1B | $5.4B | $7.8B | $2.0B | $2.1B | $1.9B | $2.6B |
| P/E Ratio → | -4.48 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.82 | 3.37 | 6.80 | 8.10 | 8.92 | 16.22 | 31.08 | 23.30 | 42.03 | 753.82 | 20927.48 |
| P/B Ratio | — | — | 14.52 | 12.77 | 9.19 | 6.18 | 7.30 | 3.70 | 3.55 | 5.13 | 5.87 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RARE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.62 | 6.56 | 7.71 | 8.64 | 15.47 | 28.62 | 19.47 | 39.83 | 715.35 | 19716.06 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
RARE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Ultragenyx Pharmaceutical Inc. earns an operating margin of -79.5%. Operating margins have expanded from -131.1% to -79.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -607.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.8% | 83.8% | 86.3% | 89.6% | 92.2% | 95.4% | 97.7% | 91.3% | 97.8% | 100.0% | -137647.4% |
| Operating Margin | -79.5% | -79.5% | -95.7% | -131.1% | -178.6% | -108.6% | -121.8% | -409.0% | -721.2% | -12593.5% | -186471.4% |
| Net Profit Margin | -85.4% | -85.4% | -101.6% | -139.7% | -194.7% | -129.2% | -68.8% | -388.3% | -383.7% | -11567.3% | -184867.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -607.5% | -607.5% | -211.7% | -193.2% | -111.0% | -43.7% | -20.6% | -63.8% | -39.8% | -70.5% | -48.9% |
| ROA | -37.9% | -37.9% | -38.0% | -40.0% | -46.1% | -27.7% | -12.9% | -43.4% | -32.7% | -58.6% | -44.7% |
| ROIC | -89.4% | -89.4% | -343.7% | -239.7% | -107.2% | -50.0% | -66.4% | -84.5% | -71.6% | -82.8% | -49.6% |
| ROCE | -46.4% | -46.4% | -45.2% | -45.6% | -49.4% | -26.2% | -25.4% | -50.6% | -69.8% | -73.1% | -49.0% |
RARE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $842M ($1.3B total debt minus $434M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.15 | 0.16 | 0.09 | 0.05 | 0.04 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.51 | -0.62 | -0.29 | -0.29 | -0.58 | -0.61 | -0.19 | -0.26 | -0.34 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.63 | -8.63 | -8.00 | -8.22 | -15.31 | -14.40 | -4.57 | -350.93 | — | — | — |
RARE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Ultragenyx Pharmaceutical Inc.'s current ratio of 2.48x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 2.61x to 2.48x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.48 | 2.48 | 2.37 | 2.61 | 3.38 | 4.72 | 6.83 | 8.24 | 6.99 | 3.44 | 8.27 |
| Quick Ratio | 2.34 | 2.34 | 2.24 | 2.49 | 3.28 | 4.63 | 6.76 | 8.13 | 6.90 | 3.43 | 8.27 |
| Cash Ratio | 1.80 | 1.80 | 1.77 | 2.06 | 2.86 | 4.08 | 6.34 | 7.31 | 6.15 | 3.30 | 6.31 |
| Asset Turnover | — | 0.44 | 0.37 | 0.29 | 0.24 | 0.23 | 0.15 | 0.09 | 0.07 | 0.01 | 0.00 |
| Inventory Turnover | 2.10 | 2.10 | 1.70 | 1.33 | 1.06 | 0.99 | 0.47 | 0.78 | 0.16 | 0.00 | — |
| Days Sales Outstanding | — | 86.23 | 79.36 | 61.69 | 40.63 | 29.53 | 31.10 | 115.59 | 90.30 | 722.73 | — |
RARE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ultragenyx Pharmaceutical Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $99M | $91M | $74M | $70M | $68M | $61M | $57M | $50M | $42M | $40M |
Peer Comparison
Compare RARE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RAREYou | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 BMRN | $10B | 30.1 | 15.9 | 14.4 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RYTM | $7B | -30.9 | — | — | 89.7% | -101.2% | -129.5% | -70.1% | — |
 LGND | $4B | -956.0 | 322.1 | 53.4 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See RARE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RARE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RARE vs BMRN
Side-by-side business, growth, and profitability comparison vs BioMarin Pharmaceutical Inc..
Start ComparisonRARE — Frequently Asked Questions
Quick answers to the most common questions about buying RARE stock.
What is Ultragenyx Pharmaceutical Inc.'s P/E ratio?
Ultragenyx Pharmaceutical Inc.'s current P/E ratio is -4.5x. This places it at the 50th percentile of its historical range.
What is Ultragenyx Pharmaceutical Inc.'s ROE?
Ultragenyx Pharmaceutical Inc.'s return on equity (ROE) is -607.5%. The historical average is -74.7%.
Is RARE stock overvalued?
Based on historical data, Ultragenyx Pharmaceutical Inc. is trading at a P/E of -4.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Ultragenyx Pharmaceutical Inc.'s profit margins?
Ultragenyx Pharmaceutical Inc. has 83.8% gross margin and -79.5% operating margin.